Paul F. Lizzul - 22 Dec 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Reporting relationship: Chief Medical Officer
Issuer ticker: ANAB
Reported as of: 22 Dec 2025
Net transaction value: -$47,250
SEC form: 4
Accepted by SEC: 23 Dec 2025, 16:28:44 UTC
Prior SEC filing: 07 Jan 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric Loumeau, Attorney-in-Fact

Key filing fact

Paul F. Lizzul filed Form 4 for ANAPTYSBIO, INC (ANAB) on 23 Dec 2025.

Key facts

This page summarizes Paul F. Lizzul's Form 4 filing for ANAPTYSBIO, INC (ANAB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Dec 2025, 16:28.

Change

Previous filing in this sequence was filed on 07 Jan 2025.
Current net transaction value: -$47,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001711462 Primary reporting owner

Lizzul Paul F.

Relationship: Chief Medical Officer
Address: C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Eric Loumeau, Attorney-in-Fact
Signature date: 23 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANAB transaction

Common Stock

Options Exercise

Transaction value: $27,750
Shares: +1,500
Change %: +5.6%
Price: $18.50
Shares after: 28,467
Date: 22 Dec 2025
Ownership: Direct
Footnotes: F1

ANAB transaction

Common Stock

Sale

Transaction value: $75,000
Shares: -1,500
Change %: -5.3%
Price: $50.00
Shares after: 26,967
Date: 22 Dec 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANAB transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -1,500
Change %: -1.8%
Price: $0.000000
Shares after: 83,500
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500
Exercise price: $18.50
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Includes the acquisition of 1,324 shares acquired under the Company's ESPP.

Footnote F2

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025.

Footnote F3

The stock option is fully vested.

Footnote F4

In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms.